Processing your payment...
Please do not close your browser.

Insulin Market Growth, Trends and Forecast (2022-2029) By Product Type (Intermediate Acting Insulin, Short-Acting Insulin, Long-Acting Insulin) By Source (Human Recombinant Insulin, Insulin Analogs) and By Regions

12 Jul, 2022 | 136 Pages
Shares
facebook sharing button
linkedin sharing button
twitter sharing button
sharethis sharing button

Over the forecast period, the Insulin Market will register a CAGR of 4.1 % in terms of revenue and the global market size will reach USD 29 Billion by 2029.

Insulin Market Overview

The rise in the prevalence of diabetes, increased government backing, increased financing for R&D, and technical developments all contribute to the growth of the worldwide insulin market. Additionally, R&D efforts in the insulin industry are increasing as scientists worldwide work to create an improved insulin molecule for diabetic patients that boosts effectiveness and reduces negative effects. Additionally, the absence of a prescription price cap legislation is expected to boost the market because numerous major pharmaceutical firms are raising the cost of generic medications like insulin. Due to its mobility, convenience of use, and availability of premixed insulin conveyance devices, the global market participants may potentially take advantage of changes in this industry.

The human pancreas secretes the hormone insulin, which regulates the body's metabolism of lipids, proteins, and carbohydrates as well as blood glucose (sugar) levels. There are many strengths of insulin available; the most popular is U-100, which is used as a supplement to diet and exercise to enhance glycemic control in both children and adults. The surge in demand for human insulin analogs and attractive reimbursements are two important aspects that have contributed to the expansion of the global insulin industry.

The worldwide insulin market is additionally boosted by technological advancements in the area of human insulin delivery systems. For instance, the MiniMed 770G System, a cutting-edge diabetes control gadget, received FDA certification in August 2020. With little input from the users (caregivers), this gadget automatically checks blood sugar levels and administers the appropriate basal insulin dosages to children with type 1 diabetes.

What is our Insulin Market report scope?

 

Report Attributes

 

 

Report Details

 

Forecast Period 2022 to 2029

 

CAGR of 4.1 % during the review period (2022 to 2029).

 

By Product Type

  • Intermediate Acting Insulin
  • Short-Acting Insulin
  • Rapid Acting Insulin
  • Long-Acting Insulin

 

By Source

 

 

  • Human Recombinant Insulin
  • Insulin Analogs

By End-User

  • Home Healthcare
  • Hospitals
  • Over the Counter (OTC)
  • Clinics
  • Others

 

 

 

By Companies

  • Shanghai Fosun Pharmaceutical Co. Ltd.
  • Tonghua Dongbao
  • Eli Lilly And Company
  • Sanofi
  • Novo Nordisk A/S
  • Julphar
  • Biocon Ltd.
  • Becton
  • Dickinson And Company
  • Ypsomed Ag
  • Biodel Inc.
  • B. Braun Melsungen Ag
  • Others

 

 

 

Regions Covered

 

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

 

 

 

 

 

 

 

 

Countries Covered

  • US
  • Canada
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
  • Middle East & Africa
  • Latin America

Base Year

2022

 

Historical Year

 

 

2017 to 2021

Forecast Year

 

2022 to 2029

Number of Pages

136

 

Customization Available

 

 

Yes, the report can be customized as per your needs

Frequently Asked Questions

What are the current market size and compound annual growth rate (CAGR) of the Insulin Market during the forecast period (2022-2029)?

The Insulin Market is growing at a CAGR of 4.1 % over the next 7 years.

Who are the key players in Insulin Market?

Shanghai Fosun Pharmaceutical Co. Ltd., Tonghua Dongbao, Eli Lilly And Company, Sanofi, Novo Nordisk A/S, Julphar, Biocon Ltd., Becton, Dickinson And Company, Ypsomed Ag, Biodel Inc., B. Braun Melsungen Ag, Others, Others.

What region does this Insulin Market report cover?

North America (the United States, Canada, and Mexico), Europe (Germany, France, UK, Russia, and Italy), Asia-Pacific (China, Japan, Korea, India, and Southeast Asia), South America (Brazil, Argentina, Colombia, etc.), The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)

What is the significant Product Type of the Insulin Market?

Intermediate Acting Insulin, Short-Acting Insulin, Rapid Acting Insulin, Long-Acting Insulin.

What are the significant sources of the Insulin Market?

Human Recombinant Insulin, Insulin Analogs.

Who are the Major Players in Insulin Market?

Market Growth Reports lists all the Insulin Market companies that are presently striving to reduce the impact of the Covid-19 pandemic on the Market- Shanghai Fosun Pharmaceutical Co. Ltd., Tonghua Dongbao, Eli Lilly And Company, Sanofi, Novo Nordisk A/S, Julphar, Biocon Ltd., Becton, Dickinson And Company, Ypsomed Ag, Biodel Inc., B. Braun Melsungen Ag, Others, Others

Industry News:

In October 2019, the formal introduction of Semglee was announced by Mylan N.V., a multinational generic and specialty medicines firm, and Biocon Ltd., an innovation-led fully integrated biopharmaceutical company. It is prescription insulin used to manage excessive blood sugar in both type 1 and type 2 diabetic children and adults.

What are the major Product Type, Sources, and End Users of the Insulin Market?

By Product Type, it is segmented into

  • Intermediate Acting Insulin
  • Short-Acting Insulin
  • Rapid Acting Insulin
  • Long-Acting Insulin

By Source it is segmented into

  • Human Recombinant Insulin
  • Insulin Analogs

By End User, it is segmented into

  • Home Healthcare
  • Hospitals
  • Over the Counter (OTC)
  • Clinics

Insulin Market Regional Analysis

The worldwide insulin market has been divided into five geographic segments: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

During the projected period, North America is anticipated to be the insulin market's largest consumer. Several important manufacturers, like Eli Lilly and Company and Becton, Dickinson, and Company, are present in the area, which has a considerable impact on the market.

Additionally, the market in North America is projected to be driven by the increasing incidence of diabetes caused by sedentary lifestyles in the U.S. and Canada as well as the formal introduction of innovative medications. Additionally, the region's rising diabetes awareness and obesity incidence are driving up the demand for insulin there.

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Rest of the World
    • Middle East & Africa
    • Latin America
  1. INTRODUCTION
    1. MARKET DEFINITION
    2. MARKET DYNAMICS
    3. MARKET SEGMENTATION
    4. REPORT TIMELINES
    5. KEY STAKEHOLDERS
  2. RESEARCH METHODOLOGY
    1. DATA MINING
      1. SECONDARY RESEARCH
      2. PRIMARY RESEARCH
      3. SUBJECT MATTER EXPERT ADVICE
    2. QUALITY CHECK
    3. FINAL REVIEW
      1. DATA TRIANGULATION
      2. BOTTOM-UP APPROACH
      3. TOP-DOWN APPROACH
      4. RESEARCH FLOW
  3. EXECUTIVE SUMMARY
    1. INTRODUCTION
    2. GLOBAL INSULIN MARKET BY PRODUCT TYPE
    3. GLOBAL INSULIN MARKET BY SOURCE
    4. GLOBAL INSULIN MARKET BY END-USER
  4. MARKET DYNAMICS
    1. DRIVERS
      1. INCREASING DEMAND FOR MSM SUPPLEMENT
    2. RESTRAINTS
      1. STRINGENT ENVIRONMENTAL REGULATIONS
      2. HIGH COST OF MATERIALS
    3. OPPORTUNITIES
      1. INSULIN MARKET GROWTH
    4. APPLICATION OF INSULIN MARKET IMPACT OF COVID 19
  5. GLOBAL INSULIN MARKET, BY PRODUCT TYPE
    1. INTRODUCTION
    2. INTERMEDIATE-ACTING INSULIN
    3. SHORT-ACTING INSULIN
    4. RAPID-ACTING INSULIN
    5. LONG-ACTING INSULIN
  6. GLOBAL INSULIN MARKET, BY SOURCE
    1. INTRODUCTION
    2. HUMAN RECOMBINANT INSULIN
    3. INSULIN ANALOGS
  7. GLOBAL INSULIN MARKET, BY END-USER
    1. INTRODUCTION
    2. HOME HEALTHCARE
    3. HOSPITALS
    4. OVER-THE-COUNTER (OTC)
    5. CLINICS
    6. OTHERS
  8. GLOBAL INSULIN MARKET, BY REGION
    1. NORTH AMERICA
      1. US
      2. CANADA
      3. MEXICO
    2. EUROPE
      1. GERMANY
      2. FRANCE
      3. UK
      4. ITALY
      5. RUSSIA
      6. REST OF EUROPE
    3. APAC
      1. CHINA
      2. SOUTH KOREA
      3. JAPAN
      4. INDIA
      5. AUSTRALIA
      6. ASEAN
      7. REST OF APAC
    4. MIDDLE EAST AND AFRICA
      1. SAUDI ARABIA
      2. UAE
      3. SOUTH AFRICA
      4. TURKEY
      5. REST OF MEA
    5. SOUTH AMERICA
      1. BRAZIL
      2. REST OF MEA
      3. ARGENTINA
      4. REST OF SOUTH AMERICA
  9. COMPETITIVE LANDSCAPE
    1. MERGERS, ACQUISITIONS, JOINT VENTURES, COLLABORATIONS,
    2. AND AGREEMENTS
      1. KEY DEVELOPMENT
    3. MARKET SHARE PERCENT/RANKING ANALYSIS
    4. STRATEGIES ADOPTED BY LEADING PLAYERS
  10. COMPANY PROFILES
    1. BUSINESS OVERVIEW
    2. COMPANY SNAPSHOT
    3. PRODUCT BENCHMARKING
    4. STRATEGIC INITIATIVES
      1. SHANGHAI FOSUN PHARMACEUTICAL CO. LTD.
      2. TONGHUA DONGBAO
      3. ELI LILLY AND COMPANY
      4. SANOFI
      5. NOVO NORDISK A/S
      6. JULPHAR
      7. BIOCON LTD.
      8. BECTON
      9. DICKINSON AND COMPANY
      10. YPSOMED AG
      11. BIODEL INC.
      12. B. BRAUN MELSUNGEN AG
      13. OTHERS

 

 

SECONDARY RESEARCH
Secondary Research Information is collected from a number of publicly available as well as paid databases. Public sources involve publications by different associations and governments, annual reports and statements of companies, white papers and research publications by recognized industry experts and renowned academia etc. Paid data sources include third party authentic industry databases.

PRIMARY RESEARCH
Once data collection is done through secondary research, primary interviews are conducted with different stakeholders across the value chain like manufacturers, distributors, ingredient/input suppliers, end customers and other key opinion leaders of the industry. Primary research is used both to validate the data points obtained from secondary research and to fill in the data gaps after secondary research.

MARKET ENGINEERING
The market engineering phase involves analyzing the data collected, market breakdown and forecasting. Macroeconomic indicators and bottom-up and top-down approaches are used to arrive at a complete set of data points that give way to valuable qualitative and quantitative insights. Each data point is verified by the process of data triangulation to validate the numbers and arrive at close estimates.

EXPERT VALIDATION
The market engineered data is verified and validated by a number of experts, both in-house and external.

REPORT WRITING/ PRESENTATION
After the data is curated by the mentioned highly sophisticated process, the analysts begin to write the report. Garnering insights from data and forecasts, insights are drawn to visualize the entire ecosystem in a single report.

Request A Sample

Please Choose License Type

  • Single User License
    $2500
  • Site License
    $3000
  • Global License
    $5000

How can we help you?

Reach us with your research requirements and we shall provide the optimum solution to suit your needs.

Curioust about Multiple Reports?

Discounts available for multiple report purchases.

Contact Us

Our Clients

  • Korean Institute of Tuberculosis
  • Sanyo chemical Industries LTD
  • Novartis
  • Hisamitsu
  • Pfizer
  • AbbVie
  • RevHealth
  • Zeon Corporation
  • Abbott (Established Pharmaceutical Products)
  • Sinopharm (pharmaceutical distribution segment)
  • Takeda Pharmaceutical
  • Gilead Sciences
  • Sartorius
  • Zavation
  • Permobil
  • Ansell
  • Cefla